-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎ WuXi AppTec content team editor
Astellas Pharma and Seagen today announced the latest trial results
Urothelial carcinoma is the most common type of bladder cancer, accounting for about 90% of all bladder cancers, and can also occur in the renal pelvis, ureters, and urethra
Padcev is an antibody-conjugated drug
The EV-103 trial is a ongoing multi-cohort, open-label, multicenter Phase 1b/2 trial
Data analysis showed that the confirmed objective response rate in the Padcev and Keytruda combination groups was 64.
The security aspect is consistent
According to the published summary, these new data support the continuation of trials to test the possibility